Skip to main content
OTCMKTS:DNPUF

Sumitomo Dainippon Pharma News Headlines

$17.40
-1.35 (-7.20 %)
(As of 05/12/2021)
Add
Compare
Today's Range
$17.40
$17.40
50-Day Range
$17.40
$18.75
52-Week Range
$12.45
$18.75
Volume571 shs
Average Volume978 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Sumitomo Dainippon Pharma (OTCMKTS DNPUF) News Headlines Today

SourceHeadline
Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical TrialExscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
businesswire.com - May 13 at 8:38 AM
China Meropenem Market Report 2021-2025 with the Impact of COVID-19 on the MarketChina Meropenem Market Report 2021-2025 with the Impact of COVID-19 on the Market
ca.finance.yahoo.com - May 10 at 8:48 AM
Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology CompanyRoivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company
markets.businessinsider.com - May 3 at 12:50 PM
Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation MeetingAltavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting
ca.finance.yahoo.com - April 21 at 1:09 PM
Schizophrenia Market 2021 Growth Probability, Key Vendors and Future Scenario (PDF Report)|Johnson & Johnson Services, Dainippon Sumitomo Pharma CoSchizophrenia Market 2021 Growth Probability, Key Vendors and Future Scenario (PDF Report)|Johnson & Johnson Services, Dainippon Sumitomo Pharma Co
marketwatch.com - April 15 at 10:09 AM
Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021
benzinga.com - April 12 at 8:17 AM
Insomnia Drugs Market Research Report: Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis 2025Insomnia Drugs Market Research Report: Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis 2025
marketwatch.com - March 18 at 3:07 PM
Anti-Epileptic Drugs Market Research Revealing the Growth Rate and Business Opportunities to 2027Anti-Epileptic Drugs Market Research Revealing the Growth Rate and Business Opportunities to 2027
marketwatch.com - February 22 at 1:55 PM
Global Insomnia Treatment Market 2021: In-Depth Analysis of Industry Share, Size, Growth Outlook and Opportunities to 2025Global Insomnia Treatment Market 2021: In-Depth Analysis of Industry Share, Size, Growth Outlook and Opportunities to 2025
marketwatch.com - February 19 at 7:33 AM
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 ResultsUrovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
businesswire.com - February 12 at 7:23 PM
Myelodysplastic Syndrome Market Size 2020 by Cost Analysis, Revenue, Gross Margin Analysis, Types, Application and Forecast to 2024Myelodysplastic Syndrome Market Size 2020 by Cost Analysis, Revenue, Gross Margin Analysis, Types, Application and Forecast to 2024
marketwatch.com - February 3 at 7:21 AM
Metastatic Colorectal Cancer Market Size Anticipated to Expand at a CAGR of 2.6% (2020-30) in the 7MM in the coming decade - DelveInsightMetastatic Colorectal Cancer Market Size Anticipated to Expand at a CAGR of 2.6% (2020-30) in the 7MM in the coming decade - DelveInsight
finanznachrichten.de - February 2 at 9:58 AM
Anti-Epileptic Drugs Market Analysis, Trends, Growth, Size, Share and Forecast 2019 to 2025Anti-Epileptic Drugs Market Analysis, Trends, Growth, Size, Share and Forecast 2019 to 2025
marketwatch.com - January 30 at 8:20 AM
Heres what to expect from Sumitomo Dainippon Pharmas earningsHere's what to expect from Sumitomo Dainippon Pharma's earnings
markets.businessinsider.com - January 26 at 2:37 PM
Spirovant Continues Rapid Growth with New Headquarters and Expanded LeadershipSpirovant Continues Rapid Growth with New Headquarters and Expanded Leadership
benzinga.com - January 26 at 9:36 AM
Roivant Sciences founder to step down as CEORoivant Sciences founder to step down as CEO
msn.com - January 25 at 1:28 PM
Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO™ (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO™ (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020
markets.businessinsider.com - August 28 at 11:42 AM
Biogen Plans Filing For Failed Alzheimers Drug After New AnalysisBiogen Plans Filing For Failed Alzheimer's Drug After New Analysis
www.benzinga.com - October 22 at 9:30 AM
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.